HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

November 26, 2024

Study Completion Date

March 15, 2027

Conditions
AIDS-Related Human Papillomavirus InfectionHigh Grade Cervical Squamous Intraepithelial NeoplasiaHIV Infection
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given IM

OTHER

Saline

Given IM

Trial Locations (6)

Unknown

Moi University School of Medicine, Eldoret

UNC Project Malawi, Lilongwe

African Cancer Institute at Stellenbosch, Cape Town

University of the Witwatersrand, Johannesburg

Uganda Cancer Institute, Kampala

University of Zimbabwe, Harare

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Arkansas

OTHER

collaborator

AIDS and Cancer Specimen Resource

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of California, Los Angeles

OTHER

lead

AIDS Malignancy Consortium

NETWORK

NCT03284866 - HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV | Biotech Hunter | Biotech Hunter